Latest Recruitment News

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Cavalier Resources has boosted the net present value of its Stage 1 Crawford Gold Project by 50% to A$77.2 million in an updated Pre-Feasibility Study, despite rising costs. The company secured a US$18.7 million gold sale agreement and raised $4 million to fund pre-production activities.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.

Evion Group has secured key approvals from Madagascar’s Ministry of Mines to convert exploration permits into mining permits for its Maniry Graphite Project, backed by significant EU funding and US trade initiatives. Meanwhile, its Indian joint venture progresses a major graphite plant expansion to meet growing demand.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.

Firebird Metals has locked in a purpose-built industrial facility in Osborne Park, Perth, to house its pioneering Australian Demonstration Plant, the only fully integrated manganese concentrate-to-cathode active material facility outside China.

OpenLearning accelerated its SaaS annual recurring revenue by 35% year-on-year to $3.192 million in Q1 FY26, propelled by larger multi-year LMS contracts and ongoing AI platform enhancements.

Alexium International Group has boosted sales to $1.03 million following its Microtek Laboratories acquisition, shifting focus to manufacturing-led growth and expanding its flame-retardant and thermal regulation product lines.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.